Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.

Tagrisso rekommenderas för godkännande av CHMP för behandling av patienter med tidig EGFR-muterad lungcancer

Beslutet baseras på resultaten från  ADAURA fas III studien där Tagrisso minskade risken för sjukdom eller död med 80%

AstraZeneca’s Tagrisso (osimertinib) has been recommended for marketing authorisation in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent. If approved, Tagrisso will be indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the ADAURA Phase III trial. In the trial, Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the primary analysis population of patients with Stage II and IIIA EGFRm NSCLC, and in the overall trial population of patients with Stage IB-IIIA disease. These results were published in The New England Journal of Medicine.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have surgery with curative intent, recurrence is still common in early-stage disease. Historically, nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, have experienced recurrence within five years.1-3

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “With no targeted treatment options currently available for early-stage lung cancer patients after surgery in the EU, recurrence rates remain unacceptably high. This positive recommendation is a vital step towards introducing a targeted treatment option for these patients for the first time. It also reinforces the urgency to test all lung cancer patients for tumour mutations before making any treatment decisions to ensure that as many patients as possible can benefit from innovative therapies, like Tagrisso,when they become available.”

Tagrisso is approved to treat early-stage lung cancer in more than fifteen countries, including the US and China, and additional global regulatory reviews are ongoing. Tagrisso is also approved for the 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC and for the treatment of locally advanced or metastatic EGFR T790M mutation-positive NSCLC in the EU, the US, Japan, China and many other countries.

Liknande poster

Enhertu godkänt som behandling av patienter med metastaserad HER2-låg bröstcancer

Läs mer...

Positivt utlåtande från CHMP för Enhertu som behandling av patienter med metastaserad HER2-låg bröstcancer

Läs mer...

Imfinzi plus kemoterapi godkänd i EU som första immunterapiregimen för patienter med avancerad gallvägscancer

Läs mer...